At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 941 enrolled
Drug / intervention
Placebo +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis
In Brief
A Phase 3 clinical trial evaluating Placebo and Nemolizumab for Moderate-to-Severe Atopic Dermatitis. Completed, enrolled 941 participants across 174 sites in 14 countries.
Detailed Summary
The main purpose of the study was to assess the efficacy and safety of nemolizumab after a 16-week treatment period in adult and adolescent subjects with moderate-to-severe atopic dermatitis (AD) not adequately controlled with topical treatments.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsModerate-to-Severe Atopic Dermatitis
CountriesAustralia, Austria, Canada, Czechia, Germany, Latvia, Lithuania, Netherlands, New Zealand, Poland, South Korea, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2020202120222023202420252026
First PostedJun 2019
Enrollment StartJun 2019
Primary CompletionDec 2021
Study CompletionAug 2022
TodayJul 2026
First PostedJun 14, 2019
Enrollment StartJun 27, 2019
Primary CompletionDec 29, 2021
Study CompletionAug 11, 2022
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 7.0 years ago
Interventions
Placebodrug
Placebo
Nemolizumabdrug
Nemolizumab